The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Pulmonary vasculer changes in interstitial lung diseases
Aims: Pulmonary hypertension (PH) is commonly seen in patients with interstitial lung diseases (ILDs), and is associated with a worse prognosis. The aim of this study was to determine the prevalence of PH in patients with ILDs and identify the markers that may predict this complication without invasive procedures. For this purpose, the correlation between mean pulmonary artery pressures and diffusion test, functional assessments, such as six-minute walk test, was invastigated.
Methods: The study group included 30 patients who were diagnosed interstitial lung disease between February 2010 and February 2011. Demographic and clinical characteristics, physiological studies, sixminute-walking test and high resolution computered tomography results were prospectively collected, and compared between patients with and without PH. Pulmonary hypertension was defined by right heart catheterization and results were compared between patients with PH and with non-PH.
Results: The study cohort consisted of 30 patients, of whom 14 patients (46.6%) had PH. When compared with non-PH subjects, patients with PH exhibited lower six-minutes-walk distance (415 ± 41 m vs. 260 ± 95 m, p <0.001), increased oxygen desaturation percentage during six-minutes-walk test (12.44±5,46 & 7.12±3.48), and decreased percentage of predicted FVC% (49±13.95 & 67±11.56), percentage of predicted FEV1% (52±13.2 & 73.5±12.43), and percentage of predicted DLCO% (38.8±13,7 & 65.3±11.23).
Conclusion: As a result, if there is a doubt about the decrease of pulmonary function tests and exercise capacity, patients with ILDs have to be investigated for pulmonary hypertension. Key Words: Interstitial lung disease, pulmonary hypertension, six-minutes walk test, pulmonary functional tests.

1. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease.Eur Resp J. 2008;31(6):1357-1367.
2. Perez A, Rogers RM, Dauber JH. The diagnosis of idiopathic pulmonaryfibrosis. Am J Respir Cell Bio. 2008;29(3 Suppl):19-26.
3. McLaughlin W, Badesch DB, Delcroix M, et al. End-points and clinicaltrial design in pulmonary arterialhypertension. J Am Coll Cardiol.2009;54(1 Suppl):97-107.
4. Rose-Jones LJ, Mclaughlin VV. Pulmonary hypertension: types andtreatments. Curr Cardiol Rev. 2015;11(1):73-79.
5. Parikh R, Konstantinidis I, O&rsquo;Sullivan DM, Farber HW. Pulmonaryhypertension in patients with interstitial lung disease: a tool for earlydetection. Pulm Circ.2022.Oct;12(4):e12141.
6. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathicpulmonary fibrosis patients: a systematic literature review. Eur Respir J.2015;46(4):1113-1130.
7. C&ouml;mert SŞ, &Ccedil;ağlayan B. Pulmonary hypertension related to pulmonarydiseases or hypoxia and its treatment. Anadolu Kardiyol Derg.2010;10(2):S47-S55.
8. King CS, Shlobin OA.The trouble with group 3 pulmonaryhypertension in interstitial lung disease: dilemmas in diagnosis and theconundrum of treatment.Chest. 2020;158(4):1651-1664.
9. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF.Prevalence andoutcomes of pulmonary arterial hypertension in advanced idiopathicpulmonary fibrosis.Chest. 2006;129(3):746-752.
10. Trip P, Nossent EJ, de Man FS, et al.Severely reduced diffusion capacityin idiopathic pulmonary arterial hypertension: patient characteristicsand treatment responses.Eur Respir J. 2013;42(6):1575-1585.
11. Patel NM, Lederer DJ, Borczuk AC, Kawut SM.Pulmonaryhypertension in idiopathic pulmonary fibrosis.Chest. 2007;132(3):998-1006.
12. Hansen JE, Wasserman K. Pathophysiology of activity limitation inpatients with interstitial lung disease. Chest. 1996;109(6):1566-1576.
13. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changesin six-minute walk distance are important in diffuse parenchimal lungdisease. Respir Med. 2009;103(10):1430-1435.
14. Sonti R, Gersten RA, Barnett S, Brown AW, Nathan SD.Multimodalnoninvasive prediction of pulmonary hypertension in IPF.Clin RespirJ. 2019;13(9):567-573.
15. Baughman RP, Sparkman BK, Lower EE. Six minute walk test andhealth status assesssment in sarcoidosis. Chest. 2007;132(1):207-213.
16. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. Thesix-minute walk test predicts peak oxygen uptake and survival withadvanced heart failure. Chest. 1996;110(2):325-332.
17. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B,Rubenfire M. Oxygen desaturation on the six minute walk test andmortality in untreated pulmonary arterial hypertension. Eur Respir J.2001;17(4):647-652.
18. Bourbonnais JM, Samavati L. Clinical predictors of pulmonaryhypertension in sarcoidosis. Eur Respir J. 2008;32(2):296-302.
Volume 2, Issue 2, 2024
Page : 23-26